Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.44 |
| ▸ | KHK | P50053 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | LATS1 | O95835 | 2/20 | 0.37 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30146520 | 1.00 | DYRK1A (0.44) | DYRK1AKHKIRAK4MKNK1MKNK2 | |
| SCHEMBL21818820 | 0.85 | KIT (0.43) | DYRK1AKHKIRAK4MKNK1MKNK2 | |
| SCHEMBL30627897 | 0.85 | JAK2 (0.42) | DYRK1AKHKIRAK4MKNK1MKNK2 | |
| SCHEMBL30627853 | 0.85 | KIT (0.43) | DYRK1AKHKIRAK4MKNK1MKNK2 | |
| SCHEMBL30627882 | 0.85 | DYRK1A (0.40) | DYRK1AKHKIRAK4MKNK1MKNK2 | |
| SCHEMBL21819143 | 0.85 | JAK2 (0.42) | DYRK1AKHKIRAK4MKNK1MKNK2 | |
| SCHEMBL21819141 | 0.85 | DYRK1A (0.40) | DYRK1AKHKIRAK4MKNK1MKNK2 | |
| SCHEMBL29401968 | 0.84 | NOS3 (0.42) | DYRK1AKHKIRAK4MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL21819160 | 0.84 | KIT (0.42) | DYRK1AKHKIRAK4MKNK1MKNK2 | |
| SCHEMBL21819589 | 0.84 | DYRK1A (0.41) | DYRK1AKHKIRAK4MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545660-B2 | Crystalline forms of a farnesoid X receptor agonist | ELI LILLY AND COMPANY (US) | 2026-02-10 | — | — | US | disclosed |
| US-12491160-B2 | Formulations of a farnesoid X receptor agonist | ELI LILLY AND COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250289821-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2025-09-18 | — | — | US | disclosed |
| EP-3852748-B1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | LILLY CO ELI (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4596543-A2 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Organovo, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ORGANOVO, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11773094-B2 | Farnesoid X receptor agonists and uses thereof | ORGANOVO, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773094-B2 | Farnesoid X receptor agonists and uses thereof | ORGANOVO, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2021188695-A1 | FORMULATIONS OF A FARNESOID X RECEPTOR AGONIST | METACRINE, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188692-A1 | CRYSTALLINE FORMS OF A FARNESOID X RECEPTOR AGONIST | METACRINE, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| WO-2021188695-A1 | FORMULATIONS OF A FARNESOID X RECEPTOR AGONIST | METACRINE, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-11084817-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11084817-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| CN-113056271-A | Farnesoin X receptor agonists and uses thereof | 梅塔科林公司 | 2021-06-29 | — | — | CN | disclosed |
| CN-113056264-A | Farnesoin X receptor agonists and uses thereof | 梅塔科林公司 | 2021-06-29 | — | — | CN | disclosed |
| US-20200102308-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2020-04-02 | — | — | US | disclosed |
| US-20200102308-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2020-04-02 | — | — | US | disclosed |
| WO-2020061112-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773094-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | DYRK1A 3716/4885KHK 3675/4885IRAK4 859/4885 |
| US-12491160-B2 | Formulations of a farnesoid X receptor agonist | NR1H2, NR1H3, NR1H4 | DYRK1A 3235/4885KHK 2291/4885IRAK4 1236/4885 |
| US-12545660-B2 | Crystalline forms of a farnesoid X receptor agonist | CHRND, NR1H2, CHRNE | DYRK1A 1866/4885KHK 2326/4885IRAK4 2361/4885 |
| US-20200102308-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | DYRK1A 3716/4885KHK 3675/4885IRAK4 859/4885 |
| US-20250289821-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | DYRK1A 3716/4885KHK 3675/4885IRAK4 859/4885 |
| US-20230382913-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | DYRK1A 3716/4885KHK 3675/4885IRAK4 859/4885 |
| US-11084817-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | DYRK1A 3716/4885KHK 3675/4885IRAK4 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.